Navigation Links
LPGA Pro, Jill McGill, Encourages Indoor and Outdoor Allergy Sufferers to Challenge Their Course
Date:2/28/2008

al and perennial) and the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older.

The use of XYZAL(R) is contraindicated in: patients with a known hypersensitivity to levocetirizine or any of the ingredients of XYZAL(R) or to cetirizine (observed reactions range from urticaria to anaphylaxis); patients with end-stage renal impairment at less than 10 mL/min creatinine clearance or patients undergoing hemodialysis; and pediatric patients aged 6 to 11 years with impaired renal function.

Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness and motor coordination, such as operating machinery or driving a motor vehicle, after ingestion of XYZAL(R). Concurrent use of XYZAL(R) with alcohol or other central nervous system (CNS) depressants should be avoided because additional reductions in alertness and additional impairment of CNS performance may occur.

In clinical trials, the most common adverse reactions in greater than or equal to 2% of adult and adolescent patients (12 years of age and older) taking XYZAL(R) 2.5 mg, XYZAL(R) 5 mg, or placebo were somnolence (5%, 6%, 2%), nasopharyngitis (6%, 4%, 3%), fatigue (1%, 4%, 2%), dry mouth (3%, 2%, 1%), and pharyngitis (2%, 1%, 1%), respectively.

In clinical trials, the most common adverse reactions in greater than or equal to 2% of pediatric patients (6-12 years of age) taking XYZAL(R) 5 mg included pyrexia (4% vs 2% placebo), cough (3% vs < 1% placebo), somnolence (3% vs < 1% placebo), and epistaxis (2% vs < 1% placebo).

Please visit http://www.XYZAL.com for full prescribing information.

About Allergic Conditions

Many people suffer from the symptoms associated with common allergic conditions. The immune system of allergy sufferers over-reacts to something in the environment, leading to symptoms that affect
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
2. One Year On, ALLERCA Hypoallergenic Cats Bring Sneeze Free Companionship to Allergy and Asthma Sufferers
3. The Food Allergy & Anaphylaxis Network (FAAN) and Verus Pharmaceuticals Work Together to Raise Awareness of Food Allergies
4. Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers
5. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
6. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
7. Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg
8. MIT researcher addresses biomedical engineering challenges
9. GPhA Annual Meeting Focuses on Industry Opportunities and Challenges for 2008
10. Challenge Spreadable Butter Now Features Marteks lifesDHA(TM)
11. White Paper Details Infection Control Challenges Hospitals Must Address During Construction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Halozyme Therapeutics,Inc. (Nasdaq: HALO ), a biopharmaceutical ... today,announced that Douglas B. Muchmore, MD, has joined ... "I am thrilled to welcome an individual of ... leadership team. He is a widely respected,endocrinologist for ...
... IRVINE, Calif., Sept. 23 Endocare, Inc.,(Nasdaq: ... on the,development of minimally invasive technologies for tissue ... Association (AUA),has for the first time posted on ... cryoablation for prostate cancer, covering,primary, salvage and focal ...
... SAN FRANCISCO, Calif., Sept. 23 ,Monogram Biosciences, Inc. ... has,initiated a study, in collaboration with the Dana-Farber ... Assay in,metastatic breast cancer., In the study, ... approximately 600 tissue samples from patients with breast ...
Cached Biology Technology:Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development 2Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development 3Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development 4Best Practices Document on Cryoablation Posted on Website of American Urological Association 2Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer 2Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer 3Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer 4
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:11/21/2014)... Strict laws against distracted driving and the ... American and European automotive sector towards gesture recognition technologies. ... that are intuitive and able to retrieve information with ... New analysis from Frost & Sullivan,s Strategic ... Europe and North America ...
(Date:11/18/2014)... 17, 2014 The Parenteral Drug Association (PDA) today ... will speak and at least seven more will participate in ... Omni Shoreham Hotel in Washington D.C. , ... have significant support from the regulatory agencies in ... in our effort to help advance the use of ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... international collaborators have discovered the key to overcoming three ... growers worldwide in excess of AUS$7.8 billion. In ... Science , scientists from CSIRO Plant Industry, the University ... Center have identified a wheat gene sequence which provides ...
... Cardiovascular Research Institute, Colchester, Vermont have found that ... inhibitor type-1 (PAI-1) is profibrotic. The results, ... Experimental Biology and Medicine , implicate PAI-1 ... 2 diabetes, as a factor contributing to the ...
... Princeton, NJ February 23, 2009 - A new ... the Intergovernmental Panel on Climate Change (IPCC) 2001 Third ... increase in average global temperatures due to greenhouse gas ... of global concern. The study, published in the ...
Cached Biology News:Saving wheat crops worldwide 2Plasminogen activator inhibitor type-1 -- a potential link between heart failure and diabetes 2Lower increases in global temps could lead to greater impacts than previously thought, study finds 2Lower increases in global temps could lead to greater impacts than previously thought, study finds 3
... a K-12 strain ideally suited as an ... transformation efficiency, blue/white screening capability (with appropriate ... in high yields of excellent quality plasmid ... potentially useful as a stringent host due ...
... Zealand White or Californian 8 - 10 ... 6 hours of collection, processed within 24 ... is then thawed in a cool waterbath, ... through a 0.22 micron filter, bottled, and ...
... Host Strain Competent Cell Sets Sets ... strain combinations The most common ... E. coli is to use chemically ... prepared in the laboratory, greater efficiency, reproducibility ...
... Imager delivers high resolution CCD confocal imaging ... effective optical package that fits on your ... combined with high quantum efficiency CCD cameras, ... recording at up to 100 fps. A ...
Biology Products: